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Abstract
Objectives To relate cancer since entry into the Framingham Heart
Study with the risk of incident Alzheimer’s disease and to estimate the
risk of incident cancer among participants with and without Alzheimer’s
disease.
Design Community based prospective cohort study; nested age and
sex matched case-control study.
Setting Framingham Heart Study, USA.
Participants 1278 participants with and without a history of cancer who
were aged 65 or more and free of dementia at baseline (1986-90).
Main outcome measures Hazard ratios and 95% confidence intervals
for the risks of Alzheimer’s disease and cancer.
Results Over a mean follow-up of 10 years, 221 cases of probable
Alzheimer’s disease were diagnosed. Cancer survivors had a lower risk
of probable Alzheimer’s disease (hazard ratio 0.67, 95% confidence
interval 0.47 to 0.97), adjusted for age, sex, and smoking. The risk was
lower among survivors of smoking related cancers (0.26, 0.08 to 0.82)
than among survivors of non-smoking related cancers (0.82, 0.57 to
1.19). In contrast with their decreased risk of Alzheimer’s disease,
survivors of smoking related cancer had a substantially increased risk
of stroke (2.18, 1.29 to 3.68). In the nested case-control analysis,
participants with probable Alzheimer’s disease had a lower risk of
subsequent cancer (0.39, 0.26 to 0.58) than reference participants, as
did participants with any Alzheimer’s disease (0.38) and any dementia
(0.44).
Conclusions Cancer survivors had a lower risk of Alzheimer’s disease
than those without cancer, and patients with Alzheimer’s disease had a
lower risk of incident cancer. The risk of Alzheimer’s disease was lowest
in survivors of smoking related cancers, and was not primarily explained
by survival bias. This pattern for cancer is similar to that seen in
Parkinson’s disease and suggests an inverse association between cancer
and neurodegeneration.
Introduction
Limiteddatasuggestthatcancersurvivorshaveadecreasedrisk
ofAlzheimer’sdiseaseandthatpeoplewithAlzheimer’sdisease
have lower rates of cancer.
1-6 Evidence of an inverse relation
between Parkinson’s disease and most cancers is now
convincing.
7-13 A link between cancer and neurodegeneration is
plausible as they share several genes and biological pathways,
including inappropriate activation and deregulation of the cell
cycle.
14-22 Signaling along these pathways results in opposite
endpoints:inthecaseofcancer,uncontrolledcellproliferation,
and in the case of neurodegeneration, apoptotic cell death.
Proteins such as p53, a major regulator of apoptosis, and Pin1,
which has a dual role in cell cycle control and protein folding,
play a key part in the pathophysiology of both Alzheimer’s
disease and cancer.
15 A better understanding of the biological
links between these two families of diseases is already opening
new therapeutic horizons.
In one population based cohort study, people with prevalent
cancer had a 43% lower risk of ever developing Alzheimer’s
disease, and those with prevalent Alzheimer’s disease had a
69% lower risk of being admitted to hospital for cancer.
4
Although these results are intriguing, establishing a relation
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Research
RESEARCHbetween age related diseases is complex, and several issues
must be dealt with before concluding that this represents a true
association.
23 Because severe cognitive impairment leads to
decreased screening and reporting of cancer symptoms,
24 25 it is
difficult to know to what extent lower cancer rates in people
with Alzheimer’s disease are caused by decreased incidence or
under-diagnosis. For this reason, assessing the incidence of
Alzheimer’sdiseaseamongcancersurvivorswhoarecognitively
intact at baseline is the preferable analysis. Here the major
challenge is the problem of selective mortality, since cancer
survivors may have a lower risk of Alzheimer’s disease simply
because they are more likely to die before they can develop it.
Available studies have not sufficiently tackled the problems of
selective mortality. Additional limitations of previous analyses
aretheexclusionfromanalysisofincidentcancersthatdevelop
after baseline but before Alzheimer’s disease and reliance on
self report or medical record systems to identify cancer. We
investigatedtherelationbetweencancerandAlzheimer’sdisease
using data from the Framingham Heart Study, a prospective
cohort with frequent examinations of participants, prospective
validation of both Alzheimer’s disease and cancer, and over 50
years of follow-up.
Methods
TheFraminghamHeartStudyisalongitudinalcommunitybased
cohort study of cardiovascular risk factors that started in 1948
in Framingham, Massachusetts, United States. The original
cohortcomprised5209participants(2336menand2873women)
aged 28-62 at the first examination. In 1971, children of the
original cohort and their spouses were recruited to form the
offspringcohort(5214participants).Participantshaveundergone
direct evaluations, including a medical history, physical
examination, and laboratory testing every two years in the
original cohort and about every four years in the offspring
cohort.Thestudydesignandentrycriteriaforbothcohortshave
beendescribedindetailelsewhere.
26Participantsoftheoriginal
cohort aged 65 and older who were free of dementia and
attended examination cycle 20 (1986-90) comprise the sample
for our primary investigation (n=1278). We followed these
participants for incident dementia for a mean of 10 years. The
nested case-control study comprised participants from both the
original and the offspring cohorts (n=1485). All participants
gave written informed consent.
Ascertainment of cancer cases
We identified possible cancer cases in the Framingham study
at routine examinations or, if participants did not attend an
examination, by postal surveys or telephone interviews for
updates on health history. Cases were also identified through
surveillance of admissions to the local Framingham hospital
and from death records. Once a case was identified, we
confirmed the diagnosis from the patient’s medical records,
includingpathologyreports.Twoindependentpeoplereviewed
themedicalrecords.Mostcancerswereconfirmedbypathology
reports, and fewer than 3.4% of diagnoses were based solely on
death certificates or clinical diagnoses.
27 We coded primary
cancers using the World Health Organization ICD-O
(international classification of diseases) classification. For this
analysis we did not include non-malignant neoplasms and
non-melanoma skin cancers in the definition of cancer.
Ascertainment of dementia cases
Since examination cycle 14 in the original cohort and
examination 2 in the offspring cohort, a dementia-free cohort
of7809participantshasbeenundercontinuoussurveillancefor
the development of dementia and Alzheimer’s disease. The
Folstein mini-mental state examination
28 was administered at
regular cycle examinations, and participants who scored below
an education based cut-off point or had a 3 point decrement in
their score from a preceding examination (or 5 point decrement
overall)werereferredformoreindepthtesting.Participantsalso
underwent an indepth evaluation if they or someone in their
family reported symptoms of memory loss or were referred by
a Framingham study physician or staff member for evaluation
of neurological symptoms. A panel of at least one neurologist
andoneneuropsychologistdeterminedcasesofdementia,dates
of diagnosis, and subtypes using data, where available, from
the neurologist’s examination, neuropsychological test
performance, Framingham study records, hospital records,
information from primary care physicians, interviews with the
families,computedtomographyandmagneticresonanceimaging
records, and confirmation of autopsy findings. Dementia was
requiredtobepresentforatleastsixmonthsoffollow-upbefore
the diagnosis was confirmed. All participants identified as
having dementia had at least mild severity by the clinical
dementiaratingscoreof1ormore.CasesofAlzheimer’sdisease
met the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and Related
Disorders Association criteria for possible and probable
Alzheimer’s disease.
29 We classified dementia as any dementia
(met the criteria for any dementia, including Alzheimer’s
disease), possible Alzheimer’s disease (met the clinical criteria
forAlzheimer’sdiseasebutwithanatypicalcourseorevidence
of a second process contributing to the dementia), and probable
Alzheimer’s disease (met the criteria for Alzheimer’s disease
without evidence of another process contributing to the
dementia).
Assessment of covariates
From the baseline visit (examination 20) we obtained data on
personalcharacteristics(age,sex,andeducation)andlaboratory
testresults(homocysteinelevelsandapolipoproteinEgenotype).
We collected information on cancer risk factors (tobacco use
and body mass index) at baseline and updated this periodically
throughout the study. For the case-control study, we used the
covariates closest to the matching date.
Statistical analyses
Prospective cohort study
Participants contributed up to 22 years of follow-up from the
baseline examination to the development of dementia, death,
orthelastevaluation.WeusedCoxproportionalhazardmodels
to determine the hazard ratio and 95% confidence intervals for
the risk of any dementia, any Alzheimer’s disease (possible or
probable), and probable Alzheimer’s disease in those with and
withoutahistoryofverifiedcancer.Thecancerhistoryvariable
was updated to include cases of incident cancer that occurred
duringfollow-upafterbaseline.Wecarriedoutseparateanalyses
forparticipantswithanycancer(excludingnon-melanomaskin
cancer), smoking related cancers (oral, pharynx, larynx,
oesophagus, stomach, pancreas, lung, cervix, bladder, and
kidney)
30,andnon-smokingrelatedcancers.Theprimarymodels
were adjusted for age, sex, and smoking. We then repeated the
analysis in a smaller subset of patients with data on other risk
factors for Alzheimer’s disease: apolipoprotein E4 status,
educational level, and plasma homocysteine level.
30-32
ToexplorewhethertherelationbetweencancerandAlzheimer’s
disease might be mainly due to selective mortality, we first
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RESEARCHrestricted the analysis to participants who survived at least to
age 80. If the association was predominantly due to the death
of cancer survivors, then it should be diminished when these
patients were excluded. We then investigated the relation
between history of cancer at examination 20 (baseline) and a
different neurological outcome—namely, the subsequent risk
of incident stroke. If a decreased risk of cancer in patients with
Alzheimer’s disease was primarily due to their increased
mortalityrate,thentheywouldbeexpectedtohavealowerrate
of stroke as well.
Nested case-control study
To evaluate the relation between dementia and subsequent
cancer,wematchedeachdementiacasewithuptothreecontrols
of the same age and sex who were free of dementia at the time
of dementia diagnosis of the case (index date). Both cases and
reference participants were free of cancer as of the index date.
Participantswhoeventuallydevelopeddementiawereconsidered
potential controls up to five years before their data of dementia
diagnosis (to avoid subclinical dementia in controls). We used
Cox models to determine the hazard of incident cancer in
dementiacasescomparedwiththereferenceparticipants.Models
were adjusted for tobacco use and body mass index. Data on
covariates was taken from the examination closest to the index
date.Wecalculatedthecumulativeincidenceofcancerinthose
with and without Alzheimer’s disease adjusted for age, sex,
body mass index, and smoking.
Results
At examination 20 (baseline), 1278 participants (38.8% men)
aged 65 or older had normal cognitive status. The mean age
amongcancersurvivors(n=176)was77yearsandamongthose
with no history of cancer (n=1102) was 76 years (table 1⇓).
Educational level, positivity for apolipoprotein E4, and
homocysteine level did not differ substantially between those
with and without cancer. Overall, 323 cases of dementia were
diagnosed over a mean of 10 years of follow-up. Of these, 221
(86%) met the criteria for probable Alzheimer’s disease and 36
for possible Alzheimer’s disease (18 had Alzheimer’s disease
with stroke and 18 had both Alzheimer’s disease and vascular
dementia). Of the 66 patients with non-Alzheimer’s disease, 24
had Lewy body dementia, 15 had vascular dementia, two had
frontotemporal dementia, and 25 were classified as having
“other” dementia.
Cancer history and risk of Alzheimer’s
disease
At baseline 176 participants had a history of cancer, and during
follow-up an additional 247 people were diagnosed as having
incidentcancerbutbeforethediagnosisofAlzheimer’sdisease.
Cancers at baseline were more likely to be screening related
and non-smoking related than incident cancers (table 2⇓).
Cancers with high lethality such as those of the lung, pancreas,
and brain were much more common among incident cancers.
Cancer survivors had a substantially lower risk of probable
Alzheimer’sdisease(hazardratio0.67,95%confidenceinterval
0.47 to 0.97), adjusted for age, sex, and smoking (table 3⇓), but
the lower risks of any Alzheimer’s disease (0.81) and any
dementia (0.83) did not reach statistical significance. The risk
of probable Alzheimer’s disease was lower among survivors of
smoking related cancers (0.26, 0.08 to 0.82) than among those
with non-smoking related cancers (0.82, 0.57 to 1.19). Further
adjustment for education, apolipoprotein E4 genotype, and
homocysteine level gave slightly higher risk estimates, but the
lossofstatisticalsignificancewaspossiblyduetolimitedpower
in this smaller subset (table 3). Limiting the analysis to
participants who survived at least to age 80 did not change the
inverse association between cancer history and probable
Alzheimer’s disease (0.68, 0.47 to 0.99, table 4⇓). In contrast
with their substantially lower risk of Alzheimer’s disease,
survivors of smoking related cancer had an increased risk of
incidentstroke(2.18,1.29to3.68),whichwasalsoseenamong
those who survived to age 80 (2.25, 1.29 to 3.95).
Incident Alzheimer’s disease and risk of
cancer
Overall, 495 cases of any dementia, 49 of possible Alzheimer’s
disease, and 327 of probable Alzheimer’s disease were
prospectively identified. Up to three dementia-free controls
were matched to each case. Overall, 41 cases (8%) and 211
controls (14%) developed incident cancer. Table 5⇓ shows the
frequency of individual cancer types by case-control status. In
total, 6.9% (n=102) of controls were diagnosed as having
screening related cancer compared with 3.4% (n=17) of cases.
In the age matched group, the risk of subsequent cancer was
substantially decreased for those with any dementia (0.44, 0.32
to 0.61), any Alzheimer’s disease (0.45, 0.24 to 0.84), and
probable Alzheimer’s disease (0.39, 0.26 to 0.58, table 6⇓).
Whenadjustedforsmokingandbodymassindex,thedecreased
riskofcancerremainedstatisticallysignificantandbecameeven
lower. Over the follow-up period, 57 controls (17%) developed
probable Alzheimer’s disease.
Discussion
In this prospective cohort study, cancer survivors had a 33%
decreased risk of developing probable Alzheimer’s disease
compared with people without cancer. The “protective effect”
ofpreviouscancerwasgreaterforsmokingrelatedcancersthan
for non-smoking related cancers. The inverse association did
notchangewhenparticipantswhodiedwereexcluded,andwas
not seen when stroke was used as an alternative outcome,
suggesting it was not simply an artefact of decreased survival
in patients with cancer. In the case-control analysis, patients
with probable Alzheimer’s disease had a 61% decreased risk of
incident cancer. When all dementias were included, the risk
became slightly higher. Patients with dementia were less likely
to develop screening related cancers than those without
dementia, suggesting that at least some of the decreased risk is
because of under-diagnosis.
Strengths and limitations of the study
Our analysis has several important strengths. We prospectively
defined cancer and Alzheimer’s disease in the Framingham
Heart Study over its more than 50 years of follow-up, so that
our cases represent incident disease. Nearly all malignancies in
the population were captured. We updated our cancer variable
to include the many incident cases that occurred after baseline,
during follow-up. This strengthened the negative association
between cancer and Alzheimer’s disease (data not shown), and
suggests that analyses that do not include incident cancer may
underestimate the association. Finally, we carried out two
specific analyses to tackle the critical problem of survival bias.
Severallimitationsshouldalsobeconsidered.Firstly,ourcohort,
by definition, did not include people who died of cancer before
studybaseline.Itisunknownwhetherpeoplewhodiedofcancer
before the age of 65 would have had the same risk as those of
survivors. As in any longitudinal study, participants with long
follow-up represent a select population, and this should be kept
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RESEARCHinmindwheninterpretingourresults.Evencomplextechniques
used for missing data are not able to fully correct for this
selection bias.
33 However, the inverse association observed in
this study was not primarily due to survival bias, at least during
follow-up. We did not have the power to look at the relation
between Alzheimer’s disease and individual cancer types, or to
compare the relation between cancer and other types of
dementia.CohortsinwhichbothAlzheimer’sdiseaseandcancer
are carefully defined are by definition not of the size required
forsuchanalyses.Wewereunabletostratifyourresultsbyrace,
as the participants in our study were mainly white. Some cases
of vascular dementia were present in those who met the criteria
for possible Alzheimer’s disease, but, if anything, this would
have biased our results towards the null. Finally, owing to the
relativelysmallnumbersofpatientswithcancerinouranalysis,
we were not able to stratify analyses by whether patients had
or had not received treatment for cancer.
Comparison with previous studies
Our findings are similar to those of the only two available
prospective studies. In a longitudinal memory cohort of 594
patients, those with prevalent cancer at baseline seemed to
develop Alzheimer’s disease at a lower rate (hazard ratio 0.40,
95%confidenceinterval0.12to1.13)thanthosewithnohistory
of cancer.
3 In an analysis of the cognition cohort of the
Cardiovascular Health Study (n=3020), a history of cancer at
baselineconferredalowerriskofprobableAlzheimer’sdisease
(hazard ratio 0.57, 95% confidence interval 0.36 to 0.90).
4
Similartotheirresults,wefoundthattheinverserelationbecame
strongerasweexcludednon-Alzheimer’sandmixeddementias.
Our risk estimates for incidence of cancer among those with
and without Alzheimer’s disease were essentially the same as
that of Roe and colleague’s study (0.39, 0.21 to 0.74).
3 The
inverse relation decreased only slightly when we included all
otherdementias,anditwasclearinourcohortthatpatientswith
dementia had fewer screening related cancers. This suggests
that under-diagnosis in people with cognitive impairment
explains at least part of the decreased incidence of cancer in
patients with Alzheimer’s disease. However, it is unlikely to
explain all of it. Two studies found a substantially decreased
prevalence of cancer on autopsy among patients with
Alzheimer’s disease compared with age matched controls
without dementia.
1 5 In their second study, Roe and colleagues
found that admission to hospital for cancer was low among
patients with Alzheimer’s disease (hazard ratio 0.31, 0.12 to
0.86) but not in those with vascular dementia. Finally, in a
unique study of 2222 Japanese survivors of the atomic bomb,
peoplewithclinicallydiagnosedAlzheimer’sdiseasehada70%
decreased risk of previous cancer compared with age matched
participants without dementia, whereas those with vascular
dementia had a fourfold increased risk of cancer. Clearly it will
never be possible to completely adjust for reporting and
diagnostic bias in elderly patients with dementia, but together
thesefindingssuggestaspecificinverserelationbetweencancer
and Alzheimer’s disease.
We found that survivors of smoking related cancer had a
substantially lower risk of Alzheimer’s disease than survivors
of non-smoking related cancer—a pattern similar to that seen
in Parkinson’s disease. In a recent meta-analysis of 107 598
patients with Parkinson’s disease, the aggregate relative risk
was0.73(95%confidenceinterval0.63to0.83)foranycancer,
0.61 (0.58 to 0.65) for smoking related cancers, and 0.80 (0.77
to 0.84) for non-smoking related cancers.
7 A lower rate of
smoking related cancers might be expected in patients with
Parkinson’s disease owing to its well established negative
association with smoking,
34 but, in the case of Alzheimer’s
disease, the association with smoking was strongly positive.
35
In our analysis, higher mortality among those with smoking
related cancer did not explain the lower risk of Alzheimer’s
disease. Perhaps characteristics that allow someone to survive
a smoking related cancer are particularly protective against
neurodegeneration. That Alzheimer’s disease and Parkinson’s
disease are associated with the same unusual pattern for cancer
suggeststhepresenceofasyetuncoveredbiologicalconnections
between neurodegeneration and carcinogenesis.
Biological plausibility
Although cancer survivors may have some protection from
neurodegenerative diseases, the more hopeful significance of
these findings will come from the underlying biology that
explainsthisrelation.
14 16Ageneticpropensityagainstapoptosis
might protect people from cancer while increasing their risk of
neurodegeneration, as seen in some polymorphisms of the
tumour suppressor gene p53.
36 A specific link between
Alzheimer’s disease and cancer is the protein Pin1, a unique
enzyme that plays a part in protein folding as well as cell cycle
control.
15 17 37 38 Many tumours in humans over-express Pin1,
39
whereas its function is low in the brain tissue of people with
Alzheimer’s disease.
39-42 As Pin1 is necessary for cell division,
its inhibition causes regression of tumours,
43 whereas in mouse
models of Alzheimer’s disease its upregulation in postnatal
neuronsreversesneurodegeneration.
44Moreover,Pin1promoter
single nucleotide polymorphisms that inhibit Pin1 expression
are associated with an increased risk of Alzheimer’s disease
45
but a decreased risk of cancer.
46 Drugs that can modulate Pin1
are being sought as novel therapeutic agents.
An interesting unanswered question is whether treatment for
cancer modulates the risk of Alzheimer’s disease. In theory,
chemotherapymightprotectneuronssusceptibletoAlzheimer’s
disease by suppressing inflammation
47 or blocking entry into
the cell cycle,
48 both key steps in the pathway of
neurodegeneration. However, to our knowledge there is no
epidemiological evidence linking chemotherapy to a decreased
risk of Alzheimer’s disease. On the other hand, cognitive
impairment is a well described complication of chemotherapy
and has been associated with long term changes in brain
structure and function in animal models.
49 Survivors of breast
cancer who received adjuvant chemotherapy were more likely
to develop dementia in one study
50 but not in another.
51 Cranial
irradiation is clearly associated with neuronal damage and loss,
not neuroprotection.
52 Thus, although we did not account for
cancertherapyinouranalysis,availableevidencesuggeststhat,
if anything, it would have biased our results towards the null.
Conclusions and future work
The results of our analysis support the possibility of a true
inverse relation between cancer and Alzheimer’s disease. This
study is, however, only exploratory and further work is needed
toestablishbetterthelinkbetweenthesetwogroupsofdiseases.
Further insights will possibly be gained from analyses in large
clinical and administrative databases with the power to look at
the relation between Alzheimer’s disease and individual types
of cancer. The potential impact of cancer treatment on risk of
Alzheimer’s disease is another interesting area for future work.
Presently there are few curative treatments for cancer and not
even one disease modifying drug for Alzheimer’s disease. Our
data suggest that vulnerability to cancer may actually protect
against neurodegeneration, and vice versa. A further
understanding of the basis for this inverse relation may lead to
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RESEARCHWhat is already known on this topic
Parkinson’s disease is associated with a decreased risk of most cancers, and growing evidence suggests that cancer and
neurodegenerative diseases share genes and biological pathways
Limited data suggest an inverse relation between cancer and Alzheimer’s disease
It is, however, unclear if the association might be result from selective mortality in cancer survivors or under-diagnosis in patients with
Alzheimer’s disease
What this study adds
Survivors of any cancer had a 33% lower risk of incident Alzheimer’s disease and survivors of smoking related cancer had a 74%
decreased risk, neither explained by survival bias
Participants with incident Alzheimer’s disease had a 61% decreased risk of developing incident cancer, which may in part be due to
under-diagnosis
This unusual pattern for cancer is similar to that seen in Parkinson’s disease and suggests an inverse relation between cancer and
neurodegeneration
Tables
Table 1| Characteristics of Framingham Heart Study participants who were free of dementia at examination 20 (baseline), by history of
cancer. Values are numbers (percentages) unless stated otherwise
No history of cancer (n=1102) History of cancer (n=176) Characteristics
76 (68-96) 77 (68-96) Mean (range) age (years)
424 (38) 72 (41) Men
678 (62) 104 (59) Women
679 (67) 166 (72) Completion of secondary school
200 (20) 38 (25) Apolipoprotein E4
12.8 (3.5-61.6) 12.9 (4.1-66.7) Mean (range) homocysteine level (µmol/L)
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RESEARCHTable 2| Prevalent cancers at baseline and incident cancers diagnosed during follow-up
No (%) of cancers
Total No (n=423) Cancer types Incident (n=247) Prevalent (n=176)
96 (39) 54 (31) 150 Smoking related*
177 (72) 127 (72) 304 Non-smoking related
124 (50) 105 (60) 229 Cancers on routine screening
3 (1) 8 (5) 11 Head and neck
14 (6) 9 (5) 23 Oesophagus or stomach
28 (11) 21 (12) 49 Colon
14 (6) 6 (3) 20 Rectum
9 (4) 0 (0) 9 Pancreas
37 (15) 9 (5) 46 Lung
13 (5) 2 (1) 15 Haematological
4 (2) 2 (1) 6 Connective tissue
4 (2) 8 (5) 12 Melanoma
39 (16) 44 (25) 83 Breast
4 (2) 13 (7) 17 Uterus and endometrium
1 (0) 5 (3) 6 Cervix
4 (2) 3 (2) 7 Ovary
38 (15) 21 (12) 59 Prostate
10 (4) 17 (10) 27 Bladder
6 (2) 4 (2) 10 Kidney
5 (2) 0 (0) 5 Brain
4 (2) 3 (2) 7 Lymph nodes
5 (2) 0 (0) 5 Unknown primary
5‡ (83) 1† (17) 6 Other
*Some patients had both a smoking related and non-smoking related cancer, but only the first one was included in the analysis of overall cancer.
†Thyroid.
‡Liver, retroperitoneal, and pleural (n=1 each), gallbladder (n=2).
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RESEARCHTable 3| Association between history of cancer at examination 20 (baseline) and incident dementia in Framingham Heart Study, after
adjustment
Hazard ratio (95% CI)* No of cancers
Model and cancer types
Alzheimer’s disease
Any dementia Incident cases At baseline Probable Possible
n=220 n=256 n=322 Model 1 (n=1274)†:
0.67 (0.47 to 0.97) 0.81 (0.59 to 1.11) 0.83 (0.63 to 1.10) 247 175 All‡
0.26 (0.08 to 0.82) 0.62 (0.31 to 1.26) 0.79 (0.45 to 1.39) 96 54 Smoking related§
0.82 (0.57 to 1.19) 0.87 (0.62 to 1.21) 0.84 (0.62 to 1.13) 177 127 Non-smoking related
n=185 n=212 n=263 Model 2 (n=1037)¶:
0.76 (0.52 to 1.12) 0.90 (0.64 to 1.28) 0.92 (0.68 to 1.26) 210 133 All‡
0.34 (0.11 to 1.08) 0.62 (0.28 to 1.41) 0.66 (0.32 to 1.33) 77 40 Smoking related§
0.91 (0.61 to 1.35) 0.99 (0.68 to 1.42) 0.99 (0.72 to 1.38) 157 97 Non-smoking related
*Calculated using Cox proportional hazards modelling.
†Adjusted for age, sex, smoking, and incident cancer.
‡Does not include non-melanoma skin cancers.
§Defined as cancer of the oral cavity, pharynx, larynx, oesophagus, stomach, pancreas, lung, cervix, bladder, and kidney.
¶Additionally adjusted for apolipoprotein E4 status, education, and homocysteine level.
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RESEARCHTable 4| Association between history of cancer at examination 20 (baseline) and incident dementia in Framingham Heart Study among 995
participants who survived to at least age 80
Hazard ratio (95% CI)* No of cancers
Cancer types
Alzheimer’s disease Any dementia (n=302)
Incident cases At baseline Probable (n=209) Possible (n=244)
0.88 (0.64 to 1.20) 0.81 (0.46 to 1.46) 0.87 (0.65 to 1.16) 183 127 All
0.88 (0.62 to 1.25) 0.68 (0.34 to 1.38) 0.83 (0.60 to 1.15) 69 37 Smoking related
0.83 (0.56 to 1.21) 0.29 (0.09 to 0.90) 0.68 (0.47 to 0.99) 128 94 Non-smoking related
*Calculated using Cox proportional hazards modelling, adjusted for age, sex, smoking, and incident cancer.
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RESEARCHTable 5| Distribution of incident cancer in participants with any dementia and matched controls
No (%) of controls (n=1485) No (%) of cases (n=495) Total No Cancer type
211 (14.2) 41 (8.3) 252 Overall
144 (9.7) 27 (5.5) 171 Non-smoking related
67 (4.5) 14 (2.8) 81 Smoking related
102 (6.9) 17 (3.4) 119 Cancers on routine screening
39 (2.6) 10 (2.0) 49 Colorectal
33 (2.2) 3 (0.6) 36 Lung
31 (2.1) 4 (0.8) 35 Breast
25 (1.7) 2 (0.4) 27 Prostate
14 (0.9) 7 (1.4) 21 Bladder
10 (0.7) 2 (0.4) 12 Haematological
7 (0.5) 3 (0.6) 10 Unknown primary
7 (0.5) 1 (0.2) 8 Melanoma
6 (0.4) 1 (0.2) 7 Pancreas
6 (0.4) 0 (0.0) 6 Kidney
4 (0.3) 1 (0.2) 5 Lymph nodes
3 (0.2) 1 (0.2) 4 Stomach
4 (0.3) 0 (0.0) 4 Corpus uteri
3 (0.2) 0 (0.0) 3 Head and neck
3 (0.2) 0 (0.0) 3 Liver
2 (0.1) 1 (0.2) 3 Male breast
2 (0.1) 1 (0.2) 3 Brain
0 (0.0) 2 (0.4) 2 Oesophagus
2 (0.1) 0 (0.0) 2 Gallbladder
2 (0.1) 0 (0.0) 2 Thyroid
1 (50.0) 1 (50.0) 2 Connective tissue
2 (100.0) 0 (0.0) 2 Cervix
1 (50.0) 1 (50.0) 2 Ovary
1 (100.0) 0 (0.0) 1 Small intestine
1 (100.0) 0 (0.0) 1 Pleura
1 (100.0) 0 (0.0) 1 Bone
1 (100.0) 0 (0.0) 1 Female genitalia
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RESEARCHTable 6| Nested case-control study of confirmed dementia and incident cancer in Framingham Heart Study
Probable Alzheimer’s disease (n=327) Possible Alzheimer’s disease (n=376) Any dementia (n=495)
Baseline Hazard ratio (95% CI) No/No* Hazard ratio (95% CI) No/No* Hazard ratio (95% CI)† No/No*
Any cancer:
0.39 (0.26 to 0.58) 159/981 0.38 (0.25 to 0.56) 180/1128 0.44 (0.32 to 0.61) 252/1485 Model 1‡
0.29 (0.17 to 0.49) 111/599 0.29 (0.17 to 0.49) 123/696 0.38 (0.26 to 0.57) 175/913 Model 2§
Smoking related cancer:
0.45 (0.24 to 0.88) 58/981 0.45 (0.24 to 0.84) 66/1128 0.45 (0.26 to 0.77) 88/1485 Model 1
0.21 (0.07 to 0.58) 40/599 0.24 (0.10 to 0.61) 46/696 0.31 (0.15 to 0.65) 61/913 Model 2
Non-smoking related cancer:
0.36 (0.21 to 0.59) 110/981 0.36 (0.22 to 0.58) 126/1128 0.45 (0.31 to 0.65) 178/1485 Model 1
0.31 (0.16 to 0.59) 78/599 0.32 (0.17 to 0.59) 86/696 0.42 (0.26 to 0.67) 125/913 Model 2
*Number of cancer cases/number of reference participants.
†Hazard ratio and 95% confidence interval calculated using Cox proportional hazards modelling.
‡Matched on age and sex.
§Additionally adjusted for body mass index and smoking.
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